Project Grant R01AI187203
Award Date
8/1/25
Completion Date
7/31/29
Dollars Obligated
$3.4M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award of $533,707, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how the human papillomavirus (HPV) evades the body's natural defenses and persists in infected cells. The primary goal is to elucidate the mechanism by which the HPV E7 oncoprotein activates the YAP1 signaling pathway, enabling HPV-infected cells to remain in the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,768 to the University of New Mexico Health Sciences Center (UNM HSC) to conduct research on the mechanisms of papillomavirus tumor regression induced by MEK signaling inhibition. The 5-year project aims to understand how MEK inhibition reduces expression of the HPV oncogenes E6 and E7, leading to diminished keratinocyte proliferation and activation of innate immune responses to...
The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, awarded a $660,205 Project Grant to The University of Texas Southwestern Medical Center to develop small molecule inhibitors targeting the bromodomain-containing protein 4 (BRD4) to block human papillomavirus (HPV) genome replication. The grant aims to identify and characterize compounds that can effectively inhibit the three stages of HPV DNA replication by targeting the phosphorylated...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $630,506 to The Johns Hopkins University to develop and test a therapeutic vaccine against cervical cancer associated with variants of the human papillomavirus type 16 (HPV16). The primary goals are to: 1) characterize how different HPV16 variants evade immune system detection, 2) study the growth and tumor microenvironment of spontaneous cervical/vaginal cancers driven by HPV16...
This federal Project Grant award of $3,768,791.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research focused on understanding the mechanisms of herpesvirus nuclear egress. The principal investigator at Tufts University School of Medicine will conduct structural and functional studies on the nuclear egress complex (NEC) across different herpesvirus subfamilies, visualize the nuclear...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the dynamics and evolution of HIV Gag and GagPol processing. The $752,745 award aims to use molecular dynamics simulations, single-molecule FRET imaging, and cryo-electron tomography to probe the structure and dynamics of Gag and GagPol that enable ordered processing by the viral...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
This federal Project Grant award of $2,740,126, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to investigate the mechanisms by which HIV infection contributes to the development of oropharyngeal cancer (OPC) in people living with HIV (PWH). The key objectives are to: 1) Determine the HPV types present in OPC from PWH and how T cell-mediated anti-tumor immunity is impaired;...
This Project Grant award of $1,454,386.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental research to better understand the epigenetic regulation of the HIV-1 viral RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its linkage to modulating host innate immune signaling, with the goal of developing new treatments to neutralize deleterious...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $184,528 to Case Western Reserve University to conduct research on the role of the vaginal microbiome and antibody-bound bacteria in human papillomavirus (HPV) infection and cervical dysplasia. The key objectives are to characterize the abundance, species/genera, and functional profiles of antibody-bound and unbound vaginal bacteria in women with and...